A dispute over technology transfer rights pushed the World Health Organization (WHO) to delay its Global Action Plan on Antimicrobial Resistance (AMR) for further informal talks. Instead, the Executive Board approved a compromise drafted by Nepal and Ethiopia on Wednesday to reopen negotiations on intellectual property, specifically regarding “voluntary and mutually agreed technology transfers.” This […] Continue reading ->
Global health organisations have reacted with anger to the new US foreign aid policy, which prohibits all aid recipients, bar military, from performing or promoting abortion, “gender ideology”, or “diversity, equity and inclusion” (DEI). “Catastrophic”, “bullying”, “draconian” and “ideologically driven” – are some of their reactions to the Promoting Human Flourishing in Foreign Assistance (PHFFA) […] Continue reading ->
Senior United Nations officials and humanitarian leaders have urged Israel to reverse plans to withhold registration from more three-dozen international NGOs providing humanitarian relief in war-torn Gaza and the Israeli-occupied West Bank – warning that the move would severely undermine life-saving aid in a moment of acute humanitarian need. Israel said last Thursday that some […] Continue reading ->
The post-pandemic decline in infection-prevention practices, along with the broader crash in global health finance, are undermining progress against antimicrobial resistance –  one of the planet’s most urgent health threats. At a recent panel discussion co-hosted by the Geneva Health Forum (GHF), leading experts from WHO, academia, biotech, and patient advocacy warned that national AMR plans […] Continue reading ->
The Eleventh Conference of the Parties (COP) to the WHO Framework Convention on Tobacco Control (FCTC) concluded in Geneva on Saturday with calls to member states to take stronger action on reducing the environmental harm of tobacco use and increasing corporate liability. But political stand-offs between countries, along with industry interference, hindered major breakthroughs on […] Continue reading ->
The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates.  A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial […] Continue reading ->